ARTICLE | Product R&D

Drop the MIC

CanCure, Novelogics join Innate in a race for mAbs against soluble MICs

Mark Zipkin, Staff Writer

June 29, 2017 10:57 PM UTC

Access this Article

Request a Trial

Purchase This Article

BCIQ Company Profiles

American Association for Cancer Research

Centre for Drug Research and Development

Courier Therapeutics Inc.

Innate Pharma S.A.

BCIQ Target Profiles

CD3zeta (CD3z) (CD247)

Cytotoxic T-lymphocyte associated protein 4 (CTLA-4) (CTLA4) (CD152)

Killer cell lectin-like receptor subfamily K member 1 (NKG2D) (KLRK1) (CD314)

MHC class I polypeptide-related sequence A (MICA)

MHC class I polypeptide-related sequence B (MICB)

BCIQ Company Profiles

American Association for Cancer Research

Centre for Drug Research and Development

Courier Therapeutics Inc.

Innate Pharma S.A.

BCIQ Target Profiles

CD3zeta (CD3z) (CD247)

Cytotoxic T-lymphocyte associated protein 4 (CTLA-4) (CTLA4) (CD152)

Killer cell lectin-like receptor subfamily K member 1 (NKG2D) (KLRK1) (CD314)

MHC class I polypeptide-related sequence A (MICA)

MHC class I polypeptide-related sequence B (MICB)